Skip to Content
Merck
CN

SML1110

Adaphostin

≥98% (HPLC)

Synonym(s):

4-[[(2,5-Dihydroxyphenyl)methyl]amino]benzoic acid tricyclo[3.3.1.13,7]dec-1-yl ester, AG 957 Adamantyl Ester, NSC 680410

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C24H27NO4
CAS Number:
241127-58-2
Molecular Weight:
393.48
NACRES:
NA.77
PubChem Substance ID:
329825651
UNSPSC Code:
12352200
MDL number:
MFCD06411386

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C24H27NO4/c26-21-5-6-22(27)19(10-21)14-25-20-3-1-18(2-4-20)23(28)29-24-11-15-7-16(12-24)9-17(8-15)13-24/h1-6,10,15-17,25-27H,7-9,11-14H2/t15-,16+,17-,24-

SMILES string

O=C(C1=CC=C(NCC2=CC(O)=CC=C2O)C=C1)OC34C[C@@]5([H])C[C@@](C[C@@](C5)([H])C4)([H])C3

InChI key

YJZSUCFGHXQWDM-ONHXBKDTSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Related Categories

Biochem/physiol Actions

Adaphostin is a p210bcr/abl tyrosine kinase inhibitor and a potent inducer of myeloid cell death.
Adaphostin is a p210bcr/abl tyrosine kinase inhibitor displaying anti-proliferative activity in leukemia models, human prostate cancer cell line PC-3 and other cancer cell lines. Adaphostin is a potent inducer of myeloid cell death. Similarly to AG957, adaphostin appears to induce a degradation of WT and mutated Bcr/Abl.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000253529
0000239706
0000239706
0000253529
0000185746

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Koutaroh Okada et al.
EBioMedicine, 41, 105-119 (2019-01-22)
Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due to acquired resistance, such as secondary mutations in ALK including I1171N and G1202R. Although ceritinib or lorlatinib was shown to be

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service